JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

Search

Boston Scientific Corp.

Geschlossen

BrancheGesundheitswesen

92.17 -1.63

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

91.43

Max

93.7

Schlüsselkennzahlen

By Trading Economics

Einkommen

-40M

755M

Verkäufe

4M

5.1B

KGV

Branchendurchschnitt

50.027

90.422

EPS

0.75

Gewinnspanne

14.906

Angestellte

53,000

EBITDA

1M

1.4B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+30.88% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Feb. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-10B

139B

Vorheriger Eröffnungskurs

93.8

Vorheriger Schlusskurs

92.17

Nachrichtenstimmung

By Acuity

43%

57%

130 / 352 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Boston Scientific Corp. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Jan. 2026, 13:29 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- 2nd Update

15. Jan. 2026, 12:35 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- Update

15. Jan. 2026, 12:29 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock

22. Okt. 2025, 11:00 UTC

Ergebnisse

Boston Scientific Raises Outlook on Continued Cardiovascular Growth

24. Jan. 2026, 06:18 UTC

Akquisitionen, Fusionen, Übernahmen

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

15. Jan. 2026, 14:37 UTC

Heiße Aktien

Stocks to Watch Thursday: Goldman Sachs, Boston Scientific, BlackRock -- WSJ

15. Jan. 2026, 13:45 UTC

Akquisitionen, Fusionen, Übernahmen

Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion. -- Barrons.com

15. Jan. 2026, 12:04 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific: Penumbra Shareholders Can Elect to Receive Cash or Stock >BSX PEN

15. Jan. 2026, 12:03 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific: Acquisition to Expand Cardiovascular Portfolio >BSX PEN

15. Jan. 2026, 12:01 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific: Penumbra Deal Carriers an Enterprise Value of About $14.5 Billion >BSX

15. Jan. 2026, 12:00 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Buy Penumbra for $374/Share >BSX PEN

15. Jan. 2026, 12:00 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific Announces Agreement To Acquire Penumbra, Inc. >BSX PEN

12. Jan. 2026, 12:04 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific Sees Immaterial Impact to 2026 Adjusted EPS >BSX

12. Jan. 2026, 12:04 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific: Specific Terms of Valencia Transaction Not Disclosed >BSX

12. Jan. 2026, 12:03 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific: Valencia Focused on Development of Solutions to Treat Bladder Dysfunction >BSX

12. Jan. 2026, 12:00 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific Announces Agreement To Acquire Valencia Technologies Corporation >BSX

18. Nov. 2025, 17:06 UTC

Ergebnisse

Medtronic Stock Rises After Earnings. What Caught Investors' Attention. -- Barrons.com

18. Nov. 2025, 12:01 UTC

Ergebnisse

Medtronic Stock Rises After Earnings. What Caught Investors' Attention. -- Barrons.com

30. Okt. 2025, 12:38 UTC

Ergebnisse

Looking to Diversify Out of the AI Trade? Buy Boston Scientific Stock. -- Barrons.com

30. Okt. 2025, 12:01 UTC

Ergebnisse

Looking to Diversify Out of the AI Trade? Buy Boston Scientific Stock. -- Barrons.com

22. Okt. 2025, 10:32 UTC

Ergebnisse

Boston Scientific Sees 4Q Organic Sales Up 11%-13% >BSX

22. Okt. 2025, 10:32 UTC

Ergebnisse

Boston Scientific Sees 4Q Sales Up 14.5-16.5% >BSX

22. Okt. 2025, 10:31 UTC

Ergebnisse

Boston Scientific Sees 2025 Organic Sales Up About 15.5% >BSX

22. Okt. 2025, 10:31 UTC

Ergebnisse

Boston Scientific Sees 2025 Sales Up About 20% >BSX

22. Okt. 2025, 10:30 UTC

Ergebnisse

Boston Scientific Sees FY Adj EPS $3.02-Adj EPS $3.04 >BSX

22. Okt. 2025, 10:30 UTC

Ergebnisse

Boston Scientific 3Q Organic Sales Up 15.3% >BSX

22. Okt. 2025, 10:30 UTC

Ergebnisse

Boston Scientific 3Q Adj EPS 75c >BSX

22. Okt. 2025, 10:30 UTC

Ergebnisse

Boston Scientific Sees FY EPS $1.97-EPS $2.01 >BSX

22. Okt. 2025, 10:30 UTC

Ergebnisse

Boston Scientific Sees 4Q EPS 48c-EPS 52c >BSX

22. Okt. 2025, 10:30 UTC

Ergebnisse

Boston Scientific 3Q Sales $5.07B >BSX

Peer-Vergleich

Kursveränderung

Boston Scientific Corp. Prognose

Kursziel

By TipRanks

30.88% Vorteil

12-Monats-Prognose

Durchschnitt 122.75 USD  30.88%

Hoch 136 USD

Tief 100 USD

Basierend auf 17 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Boston Scientific Corp. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

17 ratings

17

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

102.95 / 104.93Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

No Evidence

Stimmung

By Acuity

130 / 352 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat